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In Parkinson’s disease (PD), both the patient and the health care provider look for ways to preserve the patient’s quality of life.
Many studies focus on the impact of depression and motor disability on poor life quality but neglect to examine the role of
anxiety. We investigated the impact of anxiety and depression on health-related quality of life in PD, using the Parkinson’s Disease
Quality of Life measure (PDQ-39). Symptoms of anxiety, more than depression, cognitive status, or motor stage, significantly
affected quality of life in 38 nondemented patients with mild-to-moderate motor disability. Stepwise regression analyses revealed
that anxiety explained 29% of the variance in the PDQ-39 sum score, and depression explained 10% of the variance beyond that
accounted for by anxiety. The findings suggest that primary management of anxiety as well as depression may be important to
optimizing the quality of life of PD patients.
1. Introduction
Parkinson’s disease (PD) is a chronic and progressive neuro-
logical condition in which nonmotor disturbances as well as
motor deficits significantly impact quality of life. The disease
is characterized by motor signs including tremor, rigidity,
bradykinesia, and disorders of gait and balance. In addition
to the difficulties in motor control, which occur as a result
of progressive loss of the dopamine-producing neurons in
the substantia nigra and dysfunction of the basal ganglia,
PD patients also frequently experience disturbances in mood
and cognition. These prevalent and disabling nonmotor
symptoms may have a greater impact on the patients’ quality
of life than do the principal motor features of PD [1–6].
Depression is the most commonly explored mood disor-
der influencing quality of life in PD and has been found to be
the best predictor overall for quality of life in several studies
[3–7]. In a population-based survey using the Parkinson’s
Disease Quality of Life Questionniare (PDQ-39) and the
Beck Depression Inventory (BDI), Schrag and colleagues
[5] found that the factor most strongly related to poorer
quality of life was depression, although motor disability was
also significantly associated. In a model predicting PDQ-39
scores, the BDI score accounted for 54% of the variance,
whereas motor disability scores accounted for only 15%. The
Global Parkinson’s Disease Survey Steering Committee [6]
also found the BDI score to be the most significant predictor
of quality of life, accounting for 58% of the variance in
PDQ-39 scores, whereas stage of motor severity and PD
medication (levodopa, either alone or in combination with
other dopaminergic drugs) together explained only 17% of
the variability of quality of life in PD.
Besides depression, anxiety disorders are a clinically
significant problem in patients with PD. The prevalence of
anxiety has typically been found to be 20–46% of PD patients
[8–12] though other studies have reported rates of up to
75% [13]. The number of patients with PD who experience
significant anxiety is greater than that of individuals with
other chronic medical conditions such as multiple sclerosis
or of the general population [13]. Anxiety is thought to have
an important impact on motivation, treatment compliance,
and cognition and can exacerbate parkinsonian symptoms
[14].
The contribution of anxiety to quality of life in PD has
been less studied, although anxiety symptoms have been
found to have a significant association with poorer quality
of life in the general population [15]. Most of the few studies
that include measures of both anxiety and quality of life have
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assessed changes in anxiety and quality of life as markers
of treatment outcome following a surgical intervention to
diminish motor symptoms, rather than directly examining
the relation of anxiety to quality of life. One such study
by Higginson and colleagues [16] found that improvement
in symptoms of anxiety following surgical treatment of
PD reflected a true reduction in anxiety as opposed to
being simply a reaction to PDmotor-symptom amelioration.
More recent studies suggest that anxiety contributes to
impaired quality of life in PD, using general psychiatric
surveys rather than specific anxiety-related instruments [17,
18]. Anxiety symptoms are often comorbid with depression
symptoms and the cooccurrence of these disorders is typi-
cally characterized by a more chronic course with significant
impairment in social and occupational functioning [19].
Improved understanding of the aspects of such symptoms
that impact quality of life would lead to increased attention
and diagnosis of mood disorders in PD and to formulation
of more appropriate treatment plans.
The aim of the present study was to investigate the rela-
tion of anxiety and depression to health-related quality of life
in PD. Clinical variables that may impact quality of life were
explored, including overall cognitive status, disease severity,
and side of motor onset, as well as age, education level, and
gender. Some studies [16, 20] suggest that certain commonly
used measures of anxiety (Beck Anxiety Inventory [BAI])
and depression (Beck Depression Inventory [BDI]) may
inflate the prevalence of anxiety and depression symptoms
in PD because of the overlap of somatic symptoms of anxiety
and depression with disease-related motor symptoms of
PD such as trembling or wobbliness in the legs. For this
reason, the present study included the Spielberger Anxiety
Inventory-Trait (STAI) and the Geriatric Depression Scale
(GDS), which are two self-report measures that include fewer
somatic items [21–23], in addition to the BAI and BDI.
The intention was to establish PD compromise on mood
measures without somatic load before concluding that mood
itself was directly related to quality of life [16, 20, 24].
We hypothesized that anxiety symptoms, like depression,
would predict quality of life more strongly than would motor
symptoms. We further expected to find anxiety to uniquely
contribute to quality of life in PD.
2. Methods
2.1. Participants. Thirty-eight nondemented individuals (20
men, 18 women) participated in the study. All participants
were recruited from the Boston Medical Center Neurology
Clinic and from local PD support groups. Each participant’s
medical record was reviewed to confirm the diagnosis of
idiopathic PD. Informed consent was obtained from each
participant. No individual had undergone surgery affecting
the thalamus, basal ganglia, or other brain regions. Motor
disability was staged using the Hoehn and Yahr scale [25]. At
the time of testing, the motor response was at its optimum
(“on” period).
The widely usedMini-Mental State Examination (MMSE
[26]) was administered as a brief screen for dementia, which
allows us to compare directly the mental status of our sample
to those reported in the literature. An MMSE score of 25
or better, indicating nondemented status, was required to
participate. Participants were questioned about psychiatric
history and current psychotropic medication.
2.2. Measures. The Dementia Rating Scale (DRS [27])
assesses cognitive functioning in five domains: attention, ini-
tiation/perseveration, construction, conceptualization, and
memory. The DRS was chosen as the cognitive status variable
because it is a widely used and accepted measure for the
assessment of neurocognitive functioning in the geriatric
population and it has demonstrated good validity in PD
patients [28].
The Hoehn and Yahr scale (H/Y) is a standard clinical
index of PD motor stage. It globally indexes signs and
symptoms of functional impairment, including postural
instability, rigidity, tremor, and bradykinesia. Stage I indi-
cates unilateral motor involvement. Stages II and III indicate
mild and moderate bilateral disability, respectively. None of
our participants was categorized as higher than Stage III (see
Section 3).
The 21-item Beck Anxiety Inventory (BAI [29]) assesses
anxiety in normal populations. A higher overall score indi-
cates more symptoms of anxiety. The BAI consists of items
that represent physiological symptoms such as numbness
and tingling, dizziness, and sweating, and items representing
“subjective” symptoms of anxiety such as fear of the worst
happening, fear of losing control, or feeling scared [29]
The Spielberger Anxiety Inventory-Trait (STAI-T [30]) is
a 20-item self-report instrument designed to assess trait
anxiety. The items are summed to produce a total score, with
higher scores indicating more trait anxiety. The STAI-T was
included as a measure of anxiety because it does not include
somatic items. The STAI-T was developed from the premise
that anxiety is the affective response when there is a perceived
or actual discrepancy between external demands and coping
resources and focused less on the physiological symptoms of
anxiety.
The Beck Depression Inventory II (BDI-II [31]) was
administered to assess depression symptomatology. The
test contains 21 items, most of which assess depressive
symptoms on a Likert scale of 0–3. The BDI-II includes
13 items that pertain to somatic symptoms of depression.
The Geriatric Depression Scale (GDS [32]) is a 20-item
measure of depression that was developed for the geriatric
population and omits questions regarding sleep and appetite
disturbance, which are symptoms that may result from PD
motor symptoms or side effects of PD medication rather
than reflecting the presence of depression in PD. Only two
items may capture somatic symptoms (energy; restless and
fidgety). Conservative cut-off scores were used with the Beck
measures when determining the percentage of the sample
to have clinically significant levels of anxiety and depressive
symptoms [16, 20].
The Parkinson’s Disease Quality of Life Questionnaire
(PDQ-39 [33]) is a disease-specific, 39-item questionnaire on
the quality of life in PD. Quality of life is a multidimensional
concept that reflects a patient’s subjective evaluation of
well-being, satisfaction, functioning, and impairment [34].
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Dimensions assessed include mobility, activities of daily liv-
ing, emotional well-being, stigma, social support, cognitive
impairment (arousal, concentration, memory, and dream-
ing/hallucinations), communication, and bodily discomfort.
Lower scores on the PDQ-39 indicate greater quality of
life. Summing all eight of the PDQ-39 dimensions and
standardizing the score on a scale of 0–100 creates the
summary index score of themeasure (PDQ-39SI). The PDQ-
39SI provides insight into the overall impact of the illness
as measured by each of the domains included. The PDQ-
39 is the most widely used disease-specific health status
questionnaire in the literature and has demonstrated high
reliability and validity in PD [33].
2.3. Scoring and Statistical Analysis. The summary index
of the PDQ-39 was calculated according to the standard
scoring algorithm [35]. All variables were converted to
standardized z scores. Spearman rank correlation coefficients
were calculated to assess the direction and magnitude of
association between variables. A stepwise hierarchical regres-
sion analysis was performed, with variables entered into the
regression model in the order of interest (anxiety first, then
depression) in accordance with information provided by our
preliminary findings [36]. Mann-Whitney U test analyses
were conducted to determine if side of motor symptom
onset, disease duration, age at onset, current age, or gender
were associated with the extent of anxiety or depression
symptoms.
3. Results
3.1. Descriptive Analysis. Thirty-eight participants with idio-
pathic PD were evaluated (Table 1). Participants included
two in Stage I (unilateral), 27 in Stage II (mild bilateral),
and nine in Stage III (moderate bilateral). For 22 of the
participants, motor symptom onset was on the left body side,
for 15 onset was on the right side, and for one onset was
reported to be bilateral.
Twelve participants followed a medication regimen that
included a combination of levodopa/carbidopa therapy alone
(n = 2) or in combination with one other dopamine agonist
(pramipexole (n = 3), pergolide (n = 1), or ropinirole, (n =
2)). Five participants were treated with levodopa/carbidopa
therapy and the catechol-O-methyltransferase inhibitor
entacapone, two participants were treated with this regi-
men (levodopa/carbidopa plus entacapone) and dopamine
agonists, and one with this regimen and the anticholin-
ergic trihexyphenidyl. Six participants were treated with
trihexyphenidyl plus either levodopa/carbidopa (n = 1) or
the dopamine agonist pramipexole (n = 1). Nine partici-
pants received levodopa/carbidopa therapy in combination
with additional dopaminergic medications and either the
monoamine oxidase type B inhibitor selegiline (n = 3) or
amantadine (n = 1), which stimulates dopamine release. Six
individuals were being treated with a dopamine agonist alone
and either selegiline (n = 1), trihexyphenidyl (n = 1), or
amantadine (n = 1).
The mean PDQ-39 score was 262.8 (standard deviation
126.3), mean MMSE was 29.0 (1.3), and mean DRS was
Table 1: PD participant characteristics; means (SD).
N 38
Age, years 62.1 (8.7)
Education, years 16.3 (2.9)
MMSE (total) 29.0 (1.3)
Men:women 20 : 18
Disease duration, years 8.4 (6.4)
MMSE: Mini-Mental State Examination.
141.7 (2.6). The mean depression scores on the BDI-II and
GDS were 10.6 (7.0) and 9.3 (6.7), respectively. The mean
anxiety score was 14.2 (8.1) on the BAI and 37.0 (10.6) on the
STAI-T. Because of the issue of somatic items, we followed
the recommendation for higher cut-off scores for each Beck
measure in PD [16, 20], which provides greater specificity
albeit with decreased sensitivity. Eleven participants (29% of
the sample) had clinically significant anxiety when evaluated
with the BAI using a highly specific cut-off score of 18 [16]
compared to 12 (32%) determined by the STAI-T cut-off
score 42. Clinically significant depression was present in eight
(21%) when determined by the BDI-II with a highly specific
cut-off score of 17 [16] and in 17 (45%) when measured
by the GDS with a standard cut-off score of 10, which has
yielded 100% sensitivity and 84% specificity for a diagnosis
of major depression in primary care settings [37].
Patients on antidepressants were all stable on their
medication for at least six months and did not differ on
their mood scores from those not on antidepressants. A total
of ten participants were taking antidepressant medication,
which included either paroxetine or sertraline. Despite the
medication, two participants still had clinically significant
anxiety, three had clinically significant depression and anx-
iety, and two had clinically significant depression, leaving
three without significant levels of anxiety and depression
with the psychiatric medication.
Comorbidity of anxiety and depression can be a concern;
we used the Beck measures because they have demonstrated
good divergent validity in regard to detection of anxiety
and depression. Six participants (16% of the sample) had
clinically significant anxiety without clinically significant
depression, three participants (8%) had clinically significant
depression without clinically significant anxiety, five (13%)
had both clinically significant anxiety and depression, and 24
(63%) did not have clinically significant anxiety or depres-
sion. Hence, there were more participants with principally
more anxiety than depression in this sample.
The percentage of anxiety and depression in the present
sample did not differ for men and women, nor for those with
motor symptom onset on the right versus the left side of the
body (Table 2), nor did there appear to be any interaction
of gender and side of onset. No significant differences were
found between the gender or side of onset subgroups on
quality of life. Mann-Whitney U test analyses revealed that
side of motor symptom onset, age at onset, and gender
were not associated with the extent of anxiety or depression
symptoms. Data were accordingly collapsed across these
variables for subsequent analyses.
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Table 2: Anxiety and depression symptoms in PD subgroups by gender and side of motor symptom onset.
Male (n = 20) Female (n = 18) LPD (n = 21) RPD (n = 16)
BDI-II 11.8 (7.3) 9.2 (6.5) 10.3 (7.4) 11.0 (6.8)
GDS 10.0 (6.2) 8.6 (7.3) 9.8 (7.6) 9.0 (5.7)
BAI 15.0 (7.4) 13.2 (9.0) 15.1 (9.2) 13.1 (6.9)
STAI-T 38.1 (7.9) 35.8 (13.1) 37.6 (11.4) 36.8 (9.9)
BDI-II: Beck Depression Inventory; GDS: Geriatric Depression Scale; BAI: Beck Anxiety Inventory; STAI-T: Spielberger Trait Anxiety Inventory; LPD: left
motor symptom onset PD; RPD: right motor symptom onset PD.
3.2. Correlation Analysis Results. Motor symptom stage, age,
education, duration of disease, anxiety, depression, and
overall cognitive status are variables that have previously
been shown to affect health-related quality of life and were
included in the correlational analysis (Table 3). The PDQ-39
summary index score correlated significantly and positively
with anxiety as measured by the BAI (ρ = .54, P < .0001)
and the STAI-T (ρ = .65, P = .002) and with depression as
measured by the BDI-II (ρ = .54, P < .0001) and the GDS
(ρ = .43, P < .0001). The PDQ-39 was inversely related
to overall cognitive status (DRS) (ρ = −.33, P = .005),
though it should be noted that none of the participants met
the criteria for dementia, including scores on the DRS or
MMSE. Those suffering frommore symptoms of anxiety and
depression demonstrated poorer quality of life. Age of disease
onset (ρ = −.16, P = .35), current age (ρ = −.04, P = .81),
duration of disease (ρ = .17, P = .32), education (ρ = −.11,
P = .51), and motor stage (H/Y score; ρ = −.10, P = .55)
did not correlate significantly with quality of life. Years of
education was inversely correlated with symptoms of anxiety
as measured by the BAI (ρ = −.43, P = .007) but not the
STAI-T (ρ = −.27, P = .11) or symptoms of depression
(GDS, ρ = −.22, P = .19; BDI-II, ρ = −.17, P = .31).
3.3. Multiple Regression Analysis Results. Using multiple
regression, the quality of life summary score was then
regressed on the linear combination of variables suggested
by the literature to impact quality of life including anxiety
symptoms (BAI), depression symptoms (BDI-II), motor
stage (H/Y), and cognition (DRS). The equation accounting
for these four variables accounted for 49% of the variance in
quality of life (F(4, 38) = 9.92, P < .001, adjusted R2 = 0.49).
Because of the good divergent validity of the Beck measures
for detecting symptoms of anxiety and depression and our
desire to be as conservative as possible in designation of
clinical anxiety and depression, we used the Beck measures
rather than the STAI-T or GDS for the regression analyses.
This decision was supported by our finding that the STAI-T
correlated significantly with the GDS (r = .79, P = .000).
Only variables that correlated significantly with the
PDQ-39 quality of life measure were entered into the step-
wise multiple regression analysis. These variables included
the anxiety score (BAI), the depression score (BDI-II),
and the overall measure of cognitive status (DRS). Anxiety
and depression demonstrated nearly equivalent beta-weights
with the BDI-II at 0.37 (t = 2.39, P < .05) and BAI at 0.34
(t = 2.23, P < .05). The beta-weight for overall cognition
(DRS) was −0.24 (t = 1.78, P > .05), which indicated that
cognition did not significantly contribute to the model. All
coefficients were in the predicted direction. Overall, anxiety
symptoms accounted for 29% of the variance in quality of life
beyond the variance accounted for by the other predictors.
Following the variance accounted for by anxiety, depression
symptoms uniquely accounted for an additional 10% of the
variance in quality of life.
4. Discussion
We found that symptoms of anxiety, more than depression,
overall cognitive status, or motor stage, affect health-
related quality of life for nondemented patients with PD.
The hypothesis that anxiety symptoms would significantly
explain variance in overall quality of life (PDQ-39) in PD
was supported, in that anxiety explained 29% of the variance
beyond that explained by the other clinical variables in
the model. Depression explained an additional 10% of the
variance not accounted for by anxiety. Together, these mood
symptoms accounted for 39% of the variance in quality
of life. Although cognitive status (DRS scores) correlated
significantly with quality of life scores, it did not explain any
further variance when anxiety and depression were in the
model, and in any case none of the participants met criteria
for dementia.
Earlier studies describing quality of life in patients with
PD did not include both anxiety and depression in the
model. Without including anxiety scores, the majority of
these studies found either depression [2–5, 7] or disease
severity [3–5] to be the most frequent associate of quality of
life. Some previous studies have shown cognitive status, as
measured by MMSE, to be an important predictor of quality
of life in PD [5], but others have not [4].
Studies have found depression to explain up to 50% of
the variance in PDQ-39 scores [1, 3, 5, 38]. The current
study found depression symptoms to predict only 10%
of the variance once anxiety was accounted for. Although
differences in sample sizes from study to study may underlie
some differences in the size of the contribution of depression,
it may also be argued that, if previous studies had included
an anxiety score in their model, their results may have been
more similar to those of the present study. It is also possible
that, because depression and anxiety symptoms often occur
together in PD (e.g., [10]), the measures used to capture
anxiety and depression are not able to differentiate these
two conditions, or an interaction between the two is present.
Arguing against this interpretation is the fact that the Beck
Parkinson’s Disease 5
Table 3: Spearman correlation matrix for variables previously demonstrated to affect health-related quality of life in PD.
STAI-T BDI-II GDS DRS H/Y AGE EDU DUR PDQ-39
BAI .68∗∗ .54∗∗ .43∗∗ −.33∗ −.31 0.05 −.43∗∗ .19 .54∗∗
STAI-T .78∗∗ .79∗∗ .23 .13 .05 −.27 −.01 .65∗∗
BDI-II .79∗∗ −.20 .09 .17 −.17 −.02 .54∗∗
GDS −.02 −.08 .09 −.22 .08 .43∗∗
DRS −.37∗ −.28 .17 −.24 .33∗
H/Y .16 −.005 .21 −.10
AGE −.09 .33∗ −.04
EDU −.09 −.11
DUR .17
∗
P < .05; ∗∗P < .01.
BAI: Beck Anxiety Inventory; STAI-T: Spielberger Trait Inventory; BDI-II: Beck Depression Inventory II; GDS: Geriatric Depression Scale; general cognitive
status: DRS: Dementia Rating Scale; H/Y: Hoehn and Yahr index of motor symptom stage; AGE: age at time of testing; EDU: years of education; DUR: years
of disease duration.
measures used in the present study have demonstrated good
divergent validity between anxiety and depression [39].
In spite of the relatively high mean DRS scores for
the sample, cognitive status was significantly associated
with quality of life, consistent with Schrag and colleagues
[5] even though it did not significantly contribute to the
model once the mood measures were included. A sample
comprising a larger range of cognitive impairment related
to PD, including dementia, may show a greater impact of
cognitive status on reported quality of life. It should also
be noted that brief screening measures such as those used
here do not capture more subtle cognitive changes that could
contribute to patients’ reported well-being. Future studies
with tests that assess specific cognitive domains may not
only further elucidate the relation of cognition to quality
of life but also help determine whether various types of
cognitive difficulties—for example, executive functioning
versus attention—differentially impact reported quality of
life in PD.
We did not find a relation between overall quality of
life and motor stage, as measured by the Hoehn and Yahr
(H/Y) scale. A study by Hobson and Meara [40] did not
find any significant correlation between motor stage, using
the H/Y scale, and scores of the SF-36, the Short Form
health related quality of life scale, whereas a study by the
Global Parkinson’s Disease Research Committee [6] found
H/Y scores and medication to explain up to 17.3% of the
variance in the PDQ-39. In our recent study, we found
correlations between only some aspects of motor severity as
indexed by the UPDRS and some of the PDQ-39 subscales:
specifically, the Rigidity and Dopamine-dependent subscales
of the UPDRS with the ADL subscale of the PDQ-39; the
Rigidity and Facial Expression subscales of the UPDRS and
the Communication subscale of the PDQ-39 [41]. A sample
with a wider range of motor severity than represented in our
present sample may well yield different results.
Anxiety is prevalent in PD, and this study highlights the
dramatic impact it has on quality of life. Despite using con-
servative cut-off scores and using measures with few somatic
items, clinically significant anxiety occurred in one-quarter
to one-third of the participants of this study, depending on
the measure used. Exactly how anxiety impacts quality of
life has yet to be clearly determined. Anxiety symptoms are
more prevalent in PD patients than in the general population
or in individuals with other chronic illnesses but are not
primarily a psychological reaction to the illness or side effects
of levodopa treatment [42]. Some investigators suggest that
people with anxiety and people with PD share an underlying
biological vulnerability. Anxiety and affective symptoms have
been associated with striatal dopamine transporter (DAT)
availability in the basal ganglia [43] as well as with PD-
related loss of catecholinergic cells of the locus ceruleus
[12, 13] and abnormalities of serotonin production [13]. It is
of substantial interest that mood disorders may precede the
onset of PDmotor symptoms by several years—even 20 years
in the case of anxiety—suggesting that mood disorders may
be prodromal indicators of PD [44, 45]. Besides anxiety itself,
an anxious (neurotic) personality has also been revealed as a
risk factor for PD much later in life [46], again suggesting a
common pathophysiology for anxiety disorders and PD.
A more direct relation between anxiety symptom ame-
lioration and improvement in PD symptoms may exist than
previously recognized. Anecdotal evidence coupled with a
study by Knight et al. [42] suggests that motor symptoms
themselves may be influenced by anxiety in PD. For example,
the disabling motor symptoms such as tremor, rigidity,
bradykinesia, and postural instability, which often occur
intermittently, have been shown to increase when the patient
is concentrating or feeling anxious [10]. Further research
exploring the direct relation of anxiety and motor symptoms
and subsequent quality of life needs to be conducted. It
is possible that treatment of anxiety in PD not only will
increase the perceived quality of life but also may help reduce
the frequency of the motor symptoms associated with the
disease.
With 39% of the variance in quality of life accounted for
by anxiety and depression symptoms, this study highlights
the importance of treating anxiety symptoms as a means
to improving the well-being of patients with PD as well
as the importance of continued emphasis on the impact
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of depressive symptoms on their overall well-being. Some
investigators have suggested a more pronounced increase in
comorbidity of anxiety and depression in patients with PD
than in healthy adults (19.3% comorbidity in PD versus 8.6%
in control adults) [47]. When depression and anxiety occur
together, they are associated with increased impairment,
a more chronic course, and poorer outcome, rendering
treatment more complex [48–50]. In PD, investigators have
suggested that anxiety often presents before the onset of
comorbid depression [51]. The strong comorbidity between
generalized anxiety disorder and major depression, the fact
that most people with this type of comorbidity report that
the onset of generalized anxiety disorder occurred before the
onset of depression, and the fact that primary generalized
anxiety disorder significantly predicts the subsequent onset
of depression and other secondary disorders raise the
question of whether early intervention and treatment of
primary anxiety would effectively prevent the subsequent
onset of secondary depression as well as improve PD patients’
quality of life.
Limitations of this study include the use of patient self-
report and the sample size. Future research can address this
issue by including more participants and adding measures
of participants’ dispositional characteristics. The use of a
brief self-report measure of anxiety and depression, although
practical, does not allow us to clarify the nature of the anxiety
and depressive disorder in this population or to determine
whether the specific type of anxiety disorder has a differential
impact on quality of life—for example, generalized anxiety
disorder versus social phobia versus panic disorder, though
all have been associated with PD [11, 52–54]. Replicating this
study with a clinician-based interview would help elucidate
whether certain types of anxiety disorders have greater
impact on quality of life and more confidently clarify the
frequency of general anxiety disorder and major depressive
disorder in PD. It would also be worthwhile to include a
more sensitive measure of PD motor symptoms, such as the
UPDRS. In a larger sample, it would be of interest to examine
data on disease characteristics associated with anxiety, such
as motor fluctuations and dyskinesias. Although the results
of this study indicate that mood symptoms are associated
with reduced quality of life in patients with PD, this study
is cross-sectional and the direction of causation among
the variable examined cannot be determined. Longitudinal
studies would help clarify the causal relation between the
variables in this study and help us to assess how quality of life
may change following treatment of anxiety and depression in
this population.
A better understanding of the factors that have the
greatest impact on a patient’s well-being is important to
informing new and improved treatment management plans
in PD. The findings of the present study support those of
other studies in the literature that mood symptoms are better
predictors of quality of life than is motor symptom stage [1–
3, 5]. The primary difference between this study and previous
studies is the inclusion of standard anxiety measures here
and the finding that anxiety, in addition to depression, is
associated with quality of life using a PD-specific quality of
life measure.
Despite the prevalence of anxiety and depression in PD,
mood symptoms are often not addressed in individuals with
this disease. In a chronic and disabling illness such as PD,
improving the aspects of well-being that most significantly
impact their perceived quality of life is vital [12]. Empirical
studies confirm that cognitive behavioral therapy (CBT) is
an effective form of therapy for the treatment of anxiety
and depression in the general population [55, 56]. Dobkin
et al. (1997) demonstrated the effectiveness of CBT for the
treatment of depression in PD [57], but further studies
are needed to also address the effectiveness of CBT and
other therapies for the treatment of anxiety in PD. The
findings of the present study suggest that primary assessment
and management of the anxiety and depression associated
with the disease may be needed to optimize the quality
of life of patients with PD, and we accordingly call for
more clinical work and research in this area. As there is no
cure for PD, empirically supported treatment of distressing
neuropsychiatric symptoms is of paramount importance in
the quest to improve the quality of life of individuals with
this disorder.
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